Masimo [MASI] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Masimo
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Masimo wins in 4 metrics, Abbott Laboratories wins in 15 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Masimo | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 129.16 | 16.75 | Abbott Laboratories |
| Price-to-Book Ratio | 7.45 | 4.59 | Abbott Laboratories |
| Debt-to-Equity Ratio | 61.58 | 26.50 | Abbott Laboratories |
| PEG Ratio | 0.60 | 0.46 | Abbott Laboratories |
| EV/EBITDA | 53.69 | 20.85 | Abbott Laboratories |
| Profit Margin (TTM) | -21.32% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | 17.12% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | 17.12% | 19.73% | Abbott Laboratories |
| Return on Equity | -22.37% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 1.84% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $145.30M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | 5.20% | 18.07% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 3.61 | 5.39 | Masimo |
| Enterprise Value | $8.26B | $238.75B | Abbott Laboratories |
| EV/Revenue Ratio | 3.83 | 5.54 | Masimo |
| Gross Profit Margin (TTM) | 62.90% | 56.44% | Masimo |
| Revenue per Share (TTM) | $40 | $25 | Masimo |
| Earnings per Share (Diluted) | $-5.15 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.23 | 0.70 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Masimo vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Masimo | 2.46% | 4.51% | 6.03% | -14.76% | -14.83% | -13.36% |
| Abbott Laboratories | -0.36% | -0.24% | 1.16% | -0.84% | 0.80% | 17.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Masimo | 5.20% | 8.76% | -39.76% | 269.00% | 412.82% | 629.52% |
| Abbott Laboratories | 18.07% | 30.65% | 21.29% | 217.47% | 424.82% | 549.05% |
News Based Sentiment: Masimo vs Abbott Laboratories
Masimo
News based Sentiment: POSITIVE
Masimo made significant strategic moves in September, including the divestiture of Sound United and an expanded partnership with Philips. These actions, coupled with positive clinical data and analyst upgrades, suggest a positive trajectory for the company, despite some mixed signals from insider activity and a recent legal settlement. The focus on core healthcare technologies positions Masimo for future growth.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories reported strong Q2 2025 earnings and raised its full-year guidance, leading to positive analyst upgrades and increased institutional investment. While the ongoing NEC litigation presents a risk, the overall narrative is positive, suggesting continued growth and profitability for the company.
Performance & Financial Health Analysis: Masimo vs Abbott Laboratories
| Metric | MASI | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $7.77B | $231.60B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 737,950 | 6,299,450 |
| 90 Day Avg. Volume | 655,770 | 5,376,593 |
| Last Close | $146.05 | $132.99 |
| 52 Week Range | $131.60 - $194.88 | $110.86 - $141.23 |
| % from 52W High | -25.06% | -5.83% |
| All-Time High | $305.21 (Nov 15, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -52.15% | -6.74% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.07% |
| Quarterly Earnings Growth | 2.21% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.21% | 0.32% |
| Operating Margin (TTM) | 0.17% | 0.20% |
| Return on Equity (TTM) | -0.22% | 0.31% |
| Debt to Equity (MRQ) | 61.58 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $19.20 | $29.05 |
| Cash per Share (MRQ) | $2.75 | $4.18 |
| Operating Cash Flow (TTM) | $176.60M | $9.04B |
| Levered Free Cash Flow (TTM) | $92.86M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | $0.00 | $1.69 |
Valuation & Enterprise Metrics Analysis: Masimo vs Abbott Laboratories
| Metric | MASI | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 129.16 | 16.75 |
| Forward P/E | 30.81 | 25.87 |
| PEG Ratio | 0.60 | 0.46 |
| Price to Sales (TTM) | 3.61 | 5.39 |
| Price to Book (MRQ) | 7.45 | 4.59 |
| Market Capitalization | ||
| Market Capitalization | $7.77B | $231.60B |
| Enterprise Value | $8.26B | $238.75B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.83 | 5.54 |
| Enterprise to EBITDA | 53.69 | 20.85 |
| Risk & Other Metrics | ||
| Beta | 1.23 | 0.70 |
| Book Value per Share (MRQ) | $19.20 | $29.05 |
Financial Statements Comparison: Masimo vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MASI | ABT |
|---|---|---|
| Revenue/Sales | $372.00M | $10.36B |
| Cost of Goods Sold | $138.00M | $4.47B |
| Gross Profit | $234.00M | $5.89B |
| Research & Development | $33.90M | $716.00M |
| Operating Income (EBIT) | $80.70M | $1.69B |
| EBITDA | $90.70M | $2.66B |
| Pre-Tax Income | $68.40M | $1.78B |
| Income Tax | $21.20M | $453.00M |
| Net Income (Profit) | $-170.70M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MASI | ABT |
|---|---|---|
| Cash & Equivalents | $130.80M | $6.53B |
| Total Current Assets | $1.18B | $23.15B |
| Total Current Liabilities | $546.50M | $13.00B |
| Long-Term Debt | $657.70M | $12.74B |
| Total Shareholders Equity | $946.40M | $49.06B |
| Retained Earnings | $1.32B | $47.72B |
| Property, Plant & Equipment | $183.60M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MASI | ABT |
|---|---|---|
| Operating Cash Flow | $62.60M | $1.42B |
| Capital Expenditures | $17.00M | $-484.00M |
| Free Cash Flow | $27.00M | $933.00M |
| Debt Repayment | $-78.80M | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | MASI | ABT |
|---|---|---|
| Shares Short | 3.72M | 18.07M |
| Short Ratio | 6.13 | 3.68 |
| Short % of Float | 0.10% | 0.01% |
| Average Daily Volume (10 Day) | 737,950 | 6,299,450 |
| Average Daily Volume (90 Day) | 655,770 | 5,376,593 |
| Shares Outstanding | 53.60M | 1.73B |
| Float Shares | 46.46M | 1.73B |
| % Held by Insiders | 0.06% | 0.01% |
| % Held by Institutions | 1.10% | 0.81% |
Dividend Analysis & Yield Comparison: Masimo vs Abbott Laboratories
| Metric | MASI | ABT |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | $0.00 | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | $0.00 | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |